Breakthrough cancer vaccine moves from mice to humans for clinical trial
By Soorya Kiran NN
March 28, 2018 13:47 +08
Ronald Levy (left) and Idit Sagiv-Barfi led the work on a possible cancer treatment that involves injecting two immune-stimulating agents directly into solid tumors.(Steve Fisch) Steve Fisch
A cancer vaccine that showed 97 percent success in removing tumors in mice has now moved to the next stage of human trials and the Stanford centre that developed it is seeking volunteers.
Though it is not exactly a vaccine by conventional term to provide lasting immunity in the body, it employs a vaccine-like injection to inject two immune stimulators that activate the immune system's T cells to eliminate tumors throughout the body.
The vaccine was developed as a part of immunotherapy that makes use of the body's immune system to attack tumors and fight cancer. "This is in its early days and we are still looking for safety and looking to make this as good as it can be," said Ronald Levy, a Stanford oncology professor and the lead author of the study. "Getting the immune system to fight cancer is one of the most recent developments in cancer," he added.
The study, undertaken by Levy, along with Stanford instructor of medicine Idit Sagiv-Barfi, was published recently in the journal Science Translational Medicine.
The treatment entails a low dose of radiation plus two rounds of the injected agents, and it involves no chemotherapy. However, it never works on all types of cancer and hence the Stanford team is looking for people with low-grade lymphoma. About 35 subjects are required for the human clinical trial.
The trial will include two drugs developed by two different companies and have been proven safe for people, said Levy. Some of the known side-effects include fever and soreness at the area where the injection was given but causes no vomiting, he noted.
After human trials, the FDA approval will be sought and it might take a year or two, he said. The vaccine approach is unique but it makes use of already FDA-approved cancer drug for the injection meant for melanoma skin cancer, he explained.
The FDA, in 2017, approved a cell therapy to treat leukemia and lymphoma known as CAR-T, where a patient's immune cells are taken from the body, genetically altered and reintroduced to attack the tumor cells.
But it is half-a-million dollar therapy with side-effects that include permanent loss of B cells, which are responsible for producing antibodies. Its success rate was 60 percent, says Michelle Hermiston of UCSF, California.
People Suffering from Type 2 Diabetes More Likely to Die from Cancer: Study
A new study says that people who have type 2 diabetes are more likely to...
Is Earth Spinning in the Wrong Direction? Research Finds Earth's Inner Core Stopped Rotating in Same Direction as Rest of the Planet
A study says that the Earth's inner core is rotating in the opposite...
Exploring Sasi Kumar Raju Addepalli's Transformative Leadership in the MDM Domains
Sasi Kumar Raju Addepalli said Master Data Management (MDM) is a critical...
Is Cancer Linked to Nuclear Silo Work? Military Officers at Nuclear Missile Base at Greater Risk of Blood Cancer
The US Space Force has highlighted concerns about possible cancer spread...
The debate over the side-effects of Covid vaccines is gaining ground...
Rick Simpson Oil, The Alternative Treatment For Chemotherapy and Radiation Now Ships Internationally
RSO aims to save lives and help those who want to treat cancer naturally...
BrainTree Nutrition: A Brain Health Supplement For Athletes, Made By Athletes
BrainTree Nutrition's products have been developed to support brain...
New Omicron Subvariant Spreading Rapidly in US, Warns CDC
XBB.1.5 is projected to comprise more than 70 per cent of viruses in some...
Why Did UK Abort Historic Virgin Orbit Launch Mid-Flight from Cosmic Girl Jet?
UK was set to achieve its historical orbit but was cut short by a...
Who is AC Charania? Indian-American Appointed as NASA's New Chief Technologist
Charania's previous experience also includes working at Blue Origin to...